08
Oct
2009
Posted in I - Series B, Q - 3Q09, R - NORTH EAST, X - Epigenetics, X - Oncology, XX - MA
Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $17.2M Series B financing. Participants include Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.